

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).

*Date:* May 19, 2023.

*Time:* 11:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Anuja Mathew, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20852, 301-761-6911, [anuja.mathew@nih.gov](mailto:anuja.mathew@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-08778 Filed 4-25-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Ancillary Studies to the IBD Genetics Consortium.

*Date:* June 20, 2023.

*Time:* 12:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Maria E. Davila-Bloom, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7017, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7637, [davila-bloom@extra.nidDK.nih.gov](mailto:davila-bloom@extra.nidDK.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-08748 Filed 4-25-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Clinical trials for age-related conditions affecting mobility.

*Date:* June 6, 2023.

*Time:* 11:00 a.m. to 1:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Maurizio Grimaldi, M.D., Ph.D., Scientific Review Officer, National

Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301-496-9374, [grimaldim2@mail.nih.gov](mailto:grimaldim2@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-08747 Filed 4-25-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

*Date:* May 11, 2023.

*Time:* 12:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Richard G. Kostriken, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, 240-669-2075, [richard.kostriken@nih.gov](mailto:richard.kostriken@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 20, 2023.  
**Tyeshia M. Roberson-Curtis**,  
*Program Analyst, Office of Federal Advisory  
 Committee Policy.*  
 [FR Doc. 2023-08776 Filed 4-25-23; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**National Institutes of Health**

**Proposed Collection; 60-Day Comment  
 Request; ABCD Study® Data Use  
 Certification (National Institute on Drug  
 Abuse)**

**AGENCY:** National Institutes of Health,  
 HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the  
 requirement of the Paperwork  
 Reduction Act of 1995 to provide  
 opportunity for public comment on  
 proposed data collection projects, the  
 National Institute on Drug Abuse  
 (NIDA) will publish periodic summaries  
 of proposed projects to be submitted to  
 the Office of Management and Budget  
 (OMB) for review and approval.

**DATES:** Comments regarding this  
 information collection are best assured  
 of having their full effect if received  
 within 60 days of the date of this  
 publication.

**FOR FURTHER INFORMATION CONTACT:** To  
 obtain a copy of the data collection  
 plans and instruments, submit

comments in writing, or request more  
 information on the proposed project,  
 contact: Dr. Elizabeth A. Hoffman,  
 Senior Scientific Program Manager,  
 Division of Extramural Research,  
 National Institute on Drug Abuse, 3WFN  
 Room 09C75 MSC 6021, Gaithersburg,  
 MD 20877, or call non-toll-free number  
 (301) 594-2265 or Email your request,  
 including your address to:  
*elizabeth.hoffman@nih.gov*. Formal  
 requests for additional plans and  
 instruments must be requested in  
 writing.

**SUPPLEMENTARY INFORMATION:** Section  
 3506(c)(2)(A) of the Paperwork  
 Reduction Act of 1995 requires: written  
 comments and/or suggestions from the  
 public and affected agencies are invited  
 to address one or more of the following  
 points: (1) Whether the proposed  
 collection of information is necessary  
 for the proper performance of the  
 function of the agency, including  
 whether the information will have  
 practical utility; (2) The accuracy of the  
 agency’s estimate of the burden of the  
 proposed collection of information,  
 including the validity of the  
 methodology and assumptions used; (3)  
 Ways to enhance the quality, utility, and  
 clarity of the information to be  
 collected; and (4) Ways to minimize the  
 burden of the collection of information  
 on those who are to respond, including  
 the use of appropriate automated,  
 electronic, mechanical, or other  
 technological collection techniques or  
 other forms of information technology.

*Proposed Collection Title:* ABCD  
 Study® Data Use Certification, 0925–  
 NEW, exp., date XX/XX/XXXX,  
 National Institute on Drug Abuse  
 (NIDA), National Institutes of Health  
 (NIH).

*Need and Use of Information  
 Collection:* The purpose of this proposal  
 is to inform data requestors about terms  
 and conditions for using data generated  
 by the Adolescent Brain Cognitive  
 Development<sup>(SM)</sup> (ABCD) Study and to  
 obtain signed agreements from  
 requestors and their institutional  
 officials attesting to their commitment  
 to abide by the data use terms and  
 conditions. These include using data for  
 research purposes; adhering to human  
 subjects research requirements; not  
 distributing the data to non-authorized  
 users; minimizing risk of participant  
 identifiability; using data ethically and  
 responsibly; and keeping the data  
 secure. Users must include a brief  
 description of their research project and  
 submit their signed data use agreements  
 to the data repository to gain access to  
 the ABCD Study® data. Users who plan  
 to conduct research studies specifically  
 on American Indian/Alaska Native (AI/  
 AN) populations must submit an  
 additional signed data use certification.

OMB approval is requested for 3  
 years. There are no costs to respondents  
 other than their time. The total  
 estimated annualized burden hours are  
 2,000.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Type of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hour
Individuals (standard DUC form) .....	1800	1	1	1800
Individuals (additional AI/AN DUC form when needed) .....	200	1	1	200
<b>Total</b> .....		<b>2000</b>		<b>2,000</b>

**Lanette A. Palmquist**,  
*Project Clearance Liaison, National Institute  
 on Drug Abuse, National Institutes of Health.*  
 [FR Doc. 2023-08743 Filed 4-25-23; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of  
 Closed Meetings**

Pursuant to section 10(d) of the  
 Federal Advisory Committee Act, as

amended, notice is hereby given of the  
 following meetings.

The meetings will be closed to the  
 public in accordance with the  
 provisions set forth in sections  
 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,  
 as amended. The grant applications and  
 the discussions could disclose  
 confidential trade secrets or commercial  
 property such as patentable material,  
 and personal information concerning  
 individuals associated with the grant  
 applications, the disclosure of which  
 would constitute a clearly unwarranted  
 invasion of personal privacy.

*Name of Committee:* Center for Scientific  
 Review Special Emphasis Panel; Special  
 Topic: Brain Imaging, Vision, Bioengineering  
 and Low Vision Technology Development.

*Date:* May 25–26, 2023.

*Time:* 8:30 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant  
 applications.

*Place:* National Institutes of Health  
 Rockledge II, 6701 Rockledge Drive,  
 Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Susan Gillmor, Ph.D.,  
 Scientific Review Officer, Center for  
 Scientific Review, National Institutes of  
 Health, 6701 Rockledge Drive, Bethesda, MD  
 20892, (240) 762-3076, *susan.gillmor@  
 nih.gov*.